SYNDAX PHARMACEUTICALS INC COM
Reported by WELLINGTON MANAGEMENT GROUP LLP
Reported 34,085 shares, down 1,877 (5.2%) from the prior quarter.
Reported value -27.7%; share count -5.2% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-12-31 | 34997000 |
| 2022-03-31 | 31873000 |
| 2022-06-30 | 61699000 |
| 2022-09-30 | 105429000 |
| 2022-12-31 | 203178599 |
| 2023-03-31 | 147918861 |
| 2023-06-30 | 155806770 |
| 2023-09-30 | 110968316 |
| 2023-12-31 | 163916627 |
| 2024-03-31 | 176991461 |
| 2024-06-30 | 150669751 |
| 2024-09-30 | 95980040 |
| 2024-12-31 | 55979494 |
| 2025-03-31 | 441793 |
| 2025-06-30 | 319207 |
| 2025-09-30 | 588107 |
| 2025-12-31 | 748586 |
| 2026-03-31 | 2886969 |
| 2026-06-30 | 2715908 |
| 2026-09-30 | 1276427 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Reduced | 67,895 | -56,346 (-45.4%) | < 0.01% | $1,276,427 | 2026-11-16 | |
| Q2 2026 | Added | 124,241 | +655 (0.5%) | < 0.01% | $2,715,908 | 2026-08-14 | |
| Q1 2026 | Added | 123,586 | +87,956 (246.9%) | < 0.01% | $2,886,969 | 2026-05-15 | |
| Q4 2025 | Reduced | 35,630 | -2,596 (-6.8%) | < 0.01% | $748,586 | 2026-02-17 | |
| Q3 2025 | Added | 38,226 | +4,141 (12.1%) | < 0.01% | $588,107 | 2025-11-14 | |
| Q2 2025 | Reduced | 34,085 | -1,877 (-5.2%) | < 0.01% | $319,207 | 2025-08-14 | |
| Q1 2025 | Reduced | 35,962 | -4,198,493 (-99.2%) | < 0.01% | $441,793 | 2025-05-13 | |
| Q4 2024 | Reduced | 4,234,455 | -751,521 (-15.1%) | 0.01% | $55,979,494 | 2025-02-12 | |
| Q3 2024 | Reduced | 4,985,976 | -2,353,028 (-32.1%) | 0.02% | $95,980,040 | 2024-11-14 | |
| Q2 2024 | Reduced | 7,339,004 | -97,612 (-1.3%) | 0.03% | $150,669,751 | 2024-08-14 | |
| Q1 2024 | Reduced | 7,436,616 | -148,605 (-2.0%) | 0.03% | $176,991,461 | 2024-05-15 | |
| Q4 2023 | Reduced | 7,585,221 | -57,225 (-0.7%) | 0.03% | $163,916,627 | 2024-02-12 | |
| Q3 2023 | Added | 7,642,446 | +198,262 (2.7%) | 0.02% | $110,968,316 | 2023-11-14 | |
| Q2 2023 | Added | 7,444,184 | +440,450 (6.3%) | 0.03% | $155,806,770 | 2023-08-14 | |
| Q1 2023 | Reduced | 7,003,734 | -979,708 (-12.3%) | 0.03% | $147,918,861 | 2023-05-12 | |
| Q4 2022 | Added | 7,983,442 | +3,596,002 (82.0%) | 0.04% | $203,178,599 | 2023-02-13 | |
| Q3 2022 | Added | 4,387,440 | +1,180,574 (36.8%) | 0.02% | $105,429,000 | 2022-11-14 | |
| Q2 2022 | Added | 3,206,866 | +1,372,936 (74.9%) | 0.01% | $61,699,000 | 2022-08-15 | |
| Q1 2022 | Added | 1,833,930 | +235,164 (14.7%) | < 0.01% | $31,873,000 | 2022-05-16 | |
| Q4 2021 | Reduced | 1,598,766 | -78,093 (-4.7%) | < 0.01% | $34,997,000 | 2022-02-11 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
250 managers reported SYNDAX PHARMACEUTICALS INC COM for Q2 2025.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| BlackRock Inc | Added | 10,456,907 | +1,914,656 | < 0.01% | $97,928,939 | 4 qtrs |
| Kynam Capital Management LP | Unchanged | 8,520,000 | 0 | 8.59% | $79,789,800 | 15 qtrs |
| The Goldman Sachs Group Inc | Added | 5,797,195 | +1,875,654 | < 0.01% | $54,290,731 | 31 qtrs |
| VANGUARD GROUP INC | Added | 5,033,934 | +162,869 | < 0.01% | $47,142,793 | 37 qtrs |
| Eversept Partners LP | Reduced | 4,065,355 | -146,915 | 3.5% | $38,072,050 | 13 qtrs |
| Bank of America Corporation | Added | 3,838,872 | +967,873 | < 0.01% | $35,951,035 | 36 qtrs |
| STATE STREET CORPORATION | Reduced | 3,442,752 | -528,980 | < 0.01% | $32,241,373 | 37 qtrs |
| STEMPOINT CAPITAL LP | Added | 2,372,634 | +774,040 | 7.13% | $22,219,717 | 7 qtrs |
| FRANKLIN RESOURCES INC | Added | 2,359,677 | +298,272 | < 0.01% | $22,098,378 | 7 qtrs |
| Point72 Asset Management L P | Reduced | 2,127,467 | -1,881,233 | 0.04% | $19,923,729 | 11 qtrs |
Filing details and methodology As reported
- Report period
- June 30, 2025
- Filed
- August 14, 2025
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 0
- Shared
- 30,504
- None
- 3,581
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.